Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ALS patients within 12 months after clinical onset at the entry~* Updated Awaji combined with El Escorial criteria: definite, probably or laboratory supported probable~* Decline of ALSFRSR being 1 or 2 during observation period of 12 weeks~* Japanese Clinical Severity Scale 1 or 2~* Those who can visit the participating medical centers~Exclusion Criteria:~* Those who have tracheostomy~* Those who had NIPPV~* %FVC\<60%~* Those who have Chronic Obstructive Pulmonary Disease (COPD)~* Those who have symptoms and signs of B12 deficiency~* Those who had edaravone less than 4 weeks prior to entry~* Those who changed the schedule and dosing of riluzole~* Those who have dementia~* Those who have the possibility of pregnancy~* Those who have serious respiratory or cardiac diseases~* Those who have malignancies~* Those who participated other clinical trials within 12 weeks~* Those who have allergies to B12 and related compounds

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): intramuscular injection of saline solution
- methylcobalamin (Type: ACTIVE_COMPARATOR): intramuscular injection of methylcobalamin

Based on this trial design, predict the completion outcome and termination type (if applicable).